Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;51(3):318-320.
doi: 10.3899/jrheum.2023-0909.

Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis

Rebecca H Haberman  1 , Ying Yin Zhou  2 , Sydney Catron  2 , Adamary Felipe  2 , Kathryn Jano  2 , Soumya M Reddy  2 , Jose U Scher  2   3
Affiliations

Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis

Rebecca H Haberman et al. J Rheumatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

RHH has served as a consultant for Janssen and UCB. SMR has served as a consultant for UCB, Novartis, Amgen, Fresenius Kabi, Abbvie and has received clinical research support from Pfizer, Janssen, and Eli Lilly. JUS has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, Amgen, UCB, BMS and AbbVie; and has received funding for investigator-initiated studies from Janssen and Pfizer. YZ, SC, AF, KJ have no disclosures.

Figures

Figure 1.
Figure 1.. Increased psychosocial stress in patients with persistent joint pain.
(A) Comparison in patient reported outcomes between those in complete remission (blue) and those with persistent joint pain (purple). On all scales, higher number represents worse outcome. (B) Correlation between number of tender joints in those with persistent pain (but without synovitis) and patient reported outcomes. Acronyms: RAPID3, Routine Assessment of Patient Index Data 3; TJC, tender joint count. ** p<0.01. *** P< 0.001
See this image and copyright information in PMC

References

    1. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137–46. - PubMed
    1. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017;377:1537–50. - PubMed
    1. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90. - PubMed
    1. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1115–25. - PubMed
    1. Ogdie A, Reddy S, Craig E, et al. Residual Symptoms in Patients with PsA Who Are in Very Low Disease Activity According to Physician Assessments [abstract]. Arthritis Rheumatol 2020;72:Suppl 10.

LinkOut - more resources